若生智能
Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · 小分子

什么是 prednisolone？

prednisolone 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Takeda
药物类别小分子
分子靶点NR3C1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

prednisolone 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedEuropean journal of endocrinology2026-08-04

Pharmacokinetics of inhaled prednisolone for adrenal crisis: an exploratory study.

Berends Julia M E JME, Vulto Annet A, van den Wijngaard Pascalle A PA, Vos Michel J MJ et al.

An adrenal crisis is a potentially life-threatening medical emergency, which requires rapid treatment with glucocorticoids. Guidelines advise immediate self-administration of hydrocortisone by intramuscular injection using an emergency management kit in case an adrenal crisis is suspected. However, self-injection is often not performed due to administration complexity or patient anxiety. Pulmonary administration of glucocorticoids may be a more patient-friendly and suitable alternative, especially when administered using a dry powder inhaler. Before advancing to the development of a dry powder inhaler, we aimed to evaluate whether the pharmacokinetics of inhaled prednisolone sodium succinate are suitable for the outpatient treatment of adrenal crisis. Twelve healthy participants (aged 23-31 years, 50% females) received two separate doses of prednisolone sodium succinate, equivalent to 56.1 and 112.2 mg prednisolone on separate occasions, administered via a nebulizer. The primary outcome was the time to reach a target plasma concentration of 200 nmol/L. The median times to achieve this plasma concentration (excluding the nebulization time of approximately 10 minutes) were 17 (13 - 23) minutes and 9 (5-11) minutes for the 56.1 and 112.2 mg doses, respectively. Furthermore, pulmonary administered prednisolone sodium succinate was well tolerated. The results of this study, particularly the short time to the target plasma concentration, indicate that prednisolone sodium succinate is rapidly absorbed via the lungs and that the pharmacokinetics of inhaled nebulized prednisolone sodium succinate are suitable for the outpatient treatment of adrenal crisis.

PMID 42549826
阅读全文 →
PubMedCase reports in oncology2026-08-04

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.

Fujii Ryohei R, Shibata Nobuhiro N, Kikawa Yuichiro Y, Fujita Shinya S et al.

Hematological immune-related adverse events associated with immune checkpoint inhibitors (ICIs) are rare, and autoimmune hemolytic anemia (AIHA) is particularly uncommon. A 71-year-old woman with stage IIA triple-negative breast cancer received perioperative pembrolizumab with carboplatin and paclitaxel. During the first treatment cycle, she developed acute severe anemia with laboratory findings consistent with hemolysis. Despite a negative direct antiglobulin test (DAT), major alternative causes of hemolysis were considered unlikely, leading to a clinical diagnosis of suspected ICI-associated AIHA. Oral prednisolone (1 mg/kg) promptly resolved hemolysis without recurrence. Pembrolizumab was discontinued; however, imaging demonstrated a clinical complete response, and subsequent surgery confirmed a pathological complete response (pCR). This case demonstrates that AIHA during ICI therapy may occur despite a negative DAT and underscores the importance of prompt recognition and corticosteroid therapy. Favorable oncologic outcomes, including pCR, may still be achieved despite early discontinuation of ICI therapy.

PMID 42549475
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-08-04

Absence of Interaction Between 5α-Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes.

Tu Haolan H, Ju Chengsheng C, McGurnaghan Stuart J SJ, Blackbourn Luke A K LAK et al.

People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α-reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co-prescription of both drugs. We performed a population-based cohort study in the Scottish Diabetes Research Network-National Diabetes Dataset (SDRN-NDS) and IQVIA Medical Research Data-UK (IMRD-UK). Patients with Type 2 diabetes aged ≥ 40 years receiving 5α-reductase inhibitors or tamsulosin, who were incident users of systemic glucocorticoids during 2006-2021 were included. We modelled the joint effect of 5α-reductase inhibitors and cumulative exposure to glucocorticoids on the risk of myocardial infarction using a time-varying Cox proportional hazards model. A total of 13 161 patients with Type 2 diabetes were included in SDRN-NDS and 15 084 in IMRD-UK. Mean age was 71.4 ± 9.6 and 72.3 ± 9.4 years, with mean follow-up of 4.7 (3.6) and 5.6 (4.0) years, respectively. Median (IQR) total glucocorticoids exposure was 210 (96-630) and 420 (200-1240) prednisolone-equivalent milligram. Risk for myocardial infarction was increased among users of 5α-reductase inhibitors (HR [95% CI]: SDRN-NDS, 1.21 [1.02-1.43]; IMRD-UK, 1.27 [1.02-1.59]) and per SD increase in cumulative glucocorticoid exposure (HR [95% CI]: SDRN-NDS, 1.09 [1.03-1.14]; IMRD-UK, 1.08 [1.01-1.15]). We did not observe a multiplicative interaction (SDRN-NDS, p = 0.44; IMRD-UK, p = 0.68) between the use of the two drugs. People with Type 2 diabetes exposed to 5α-reductase inhibitors or glucocorticoids are at an increased risk of myocardial infarction, although a multiplicative interaction between the use of the two drugs was not found.

PMID 42547757
阅读全文 →
PubMedPLoS neglected tropical diseases2026-08-03

Longitudinal performance of the ENLIST ENL severity scale in individuals with severe erythema nodosum leprosum: Responsiveness, trajectories and clinical features - a secondary analysis of the Methotrexate and Prednisolone study - MaPs in ENL.

de Barros Barbara B, Hamza Abdulnaser A, Getachew Alemtsehay A, Alinda Medhi Denisa MD et al.

Erythema nodosum leprosum (ENL) is a severe inflammatory complication of lepromatous leprosy characterised by recurrent inflammatory episodes often requiring prolonged immunosuppression. The severity of ENL can be quantified using the validated and reliable ENLIST ENL Severity Scale (EESS). The longitudinal course of ENL and how it is captured using standardised severity measures has not been well described. We prospectively evaluated the changes in ENL severity over time using the EESS in a randomised clinical trial. Ethics statement. The trial was performed according to the Helsinki Declaration as revised in 2024 and ethical approval was obtained from the London School of Hygiene & Tropical Medicine Research Ethics Committee (15762). Approval was obtained from Dr. Soetomo Hospital Ethics Committee, Indonesian Food and Drug Authority, Ethiopian Ministry of Education Ethics Committee, Ethiopian Food and Drug Authority, AHRI/ALERT Ethics Review Committee, Bombay Leprosy Project Committee, the Leprosy Mission Trust India Ethics Committee, Nepal Health Research Council and Department of Drug Administration, Nepal Government. All participants provided written informed consent before enrolment. MaPs in ENL was registered at www.clinicaltrials.gov (NCT03775460) and the Clinical Trials Registry India (CTRI/2020/11/029074). We conducted a prespecified secondary analysis of participants enrolled in the Methotrexate and Prednisolone Study in ENL, an international multicentre randomised controlled trial conducted in Ethiopia, India, Indonesia, and Nepal. Adults with severe ENL (EESS score ≥9) were followed for 60 weeks with repeated EESS assessments. Longitudinal trajectories were analysed using mixed-effects regression models. Item-level analyses characterised the clinical phenotype captured by the scale. Associations between EESS score, prednisolone exposure, and dermatology-specific health-related quality of life measured using the Dermatology Life Quality Index (DLQI) were examined. A total of 135 participants contributed 1,958 EESS assessments. Mean EESS declined rapidly during the first four weeks of treatment (-2.10 points/week; 95% CI -2.36 to -1.84; p < 0.001), increased modestly during reduction in corticosteroid dose (weeks 4-20), and gradually declined thereafter. Severe ENL (EESS score ≥9) occurred in 20.6% of visits and was characterised primarily by pain and cutaneous inflammatory manifestations. Participants who required additional prednisolone had persistently higher EESS scores and showed limited improvement compared with those who did not receive additional prednisolone. Longitudinal EESS scores were strongly correlated with the DLQI score (Spearman's ρ = 0.75; p < 0.001). The EESS captures clinically meaningful changes in ENL severity, aligns with treatment decisions, and reflects patient-reported severity over time. These findings support the use of the EESS as a robust tool for monitoring ENL severity in both clinical research and routine care.

PMID 42546085
阅读全文 →
PubMedCEN case reports2026-08-03

Maintenance of clinical remission with cyclosporine after discontinuation of prednisolone in a patient with tubulointerstitial nephritis with IgM-positive plasma cells.

Yamada Kazuki K, Nakao Shiori S, Ikeda Minori M, Suetsugu-Ishizawa Reina R et al.

Tubulointerstitial nephritis (TIN) with IgM-positive plasma cells (IgMPC-TIN) is an inflammatory disease characterized by the infiltration of IgM and CD138 dual-positive plasma cells into the renal interstitium. Steroid treatment is effective for many cases of IgMPC-TIN. However, the optimal dose and duration of steroid therapy remain poorly understood. In the present case, IgMPC-TIN was diagnosed in a 36-year-old woman with femoral head osteonecrosis. After administration of prednisolone (PSL, 20 mg/day), several markers of disease activity gradually decreased. The PSL dose was tapered to 5 mg/day for one year without TIN recurrence. To avoid exacerbation of bone lesions due to prolonged administration of PSL, cyclosporine was added to PSL. Combination treatment with 5 mg/day PSL and 100-125 mg/day cyclosporine stabilized the TIN. The patient remained stable without recurrence after further reduction and discontinuation of PSL. This case provides original evidence regarding the optimal treatment regimen for patients with IgMPC-TIN who are unsuitable for prolonged PSL administration.

PMID 42545636
阅读全文 →
PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-08-03

The Yellow Dialyzer Sign: An Unassuming Indicator of Occult Jaundice in Patients with End-stage Kidney Disease. A Case Report.

Okwuonu Chimezie Godswill CG, Balogun Rasheed Abiodun RA

In patients with end-stage renal disease (ESRD), diagnosing jaundice can be challenging because uremic skin changes and anuria may obscure classic signs such as scleral icterus and dark urine. We report a rare case in which discoloration of the hemodialysis circuit provided the first clue to occult hyperbilirubinemia. A 35-year-old woman with ESRD secondary to lupus nephritis presented for hemodialysis with features of uremia and fluid overload. Physical examination revealed no scleral icterus or skin discoloration. After a 2-hour session using a low-flux polysulfone dialyzer, a striking yellowish discoloration of the dialyzer membrane was noted. Laboratory evaluation, prompted by this observation, revealed marked unconjugated hyperbilirubinemia, elevated lactate dehydrogenase, low haptoglobin, and hemoglobinuria, confirming intravascular hemolysis complicating systemic lupus erythematosus. The yellow discoloration was attributed to the adsorption of bilirubin-albumin complexes onto the hollow fibers of the dialyzer membrane. The patient was treated with high-dose oral prednisolone for autoimmune hemolytic anemia associated with a lupus flare. Over three weeks and six subsequent dialysis sessions, hemolysis markers normalized, the yellow discoloration resolved, and her clinical condition improved significantly. Yellowish staining of the dialyzer membrane is an uncommon but important bedside sign of hyperbilirubinemia in patients undergoing dialysis. This extracorporeal indicator may reveal serious conditions such as intravascular hemolysis or hepatic dysfunction when conventional clinical signs are absent. Careful inspection of the dialysis circuit can facilitate early diagnosis, prompt treatment, and improved outcomes in this vulnerable population.

PMID 42544165
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone